Status:
COMPLETED
A Study of Single Ascending Dose of LEM-S401 in Healthy Participants
Lead Sponsor:
Lemonex Inc.
Conditions:
Cicatrix
Scar Prevention
Eligibility:
All Genders
19-65 years
Phase:
PHASE1
Brief Summary
The primary objective of the study is to assess the safety and tolerability of single dose of LEM-S401 in healthy adult subjects.
Detailed Description
This study is designed to evaluate the safety and tolerability of LEM-S401 administered as subcutaneous injection in healthy adult subjects. Overall, 18 subjects will be studied in 3 groups. Each sub...
Eligibility Criteria
Inclusion
- Healthy male and female subjects aged 19 to ≤ 65 years at screening
Exclusion
- Significant history or clinical manifestation of any hepatic, renal, neurological, psychiatric, respiratory, endocrine, hematological, tumor, genitourinary, cardiovascular, gastrointestinal, musculoskeletal, dermatological (eg, contact dermatitis, atopic dermatitis), or other
- History of drug abuse or positive urine drug screen at screening
- For all female subjects, pregnant (Urine-HCG positive) or breast-feeding subjects
Key Trial Info
Start Date :
July 11 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 3 2023
Estimated Enrollment :
19 Patients enrolled
Trial Details
Trial ID
NCT04707131
Start Date
July 11 2022
End Date
February 3 2023
Last Update
February 16 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Chungbuk National University Hospital
Cheongju-si, South Korea